Epilepsy Research

Epilepsy is a group of neurological conditions consisting of recurrent, usually unprovoked epileptic seizures. Epileptic seizures have recently been defined as "a transient occurrence of signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain". Epilepsy is one of the most common disorders of the brain, with one in 10 people suffering at least one seizure in their lifetime. There are over 40 different types of epilepsy, each of which presents with its own unique combination of seizure type, typical age of onset, EEG findings, treatment, and prognosis.

Epilepsy Research Products Targets

Products for Epilepsy Research - Page 30

Cat.No. Product Name Information/Activity
BCC6999 D-CPP-ene 117414-74-1
BCC6592 5,7-Dichlorokynurenic acid 131123-76-7
BCC7758 5,7-Dichlorokynurenic acid sodium salt 1184986-70-6
BCC6619 (±)-1-(1,2-Diphenylethyl)piperidine maleate 207461-99-2
BCC6205 DQP 1105 380560-89-4
BCC7280 Eliprodil Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM).
BCC4904 Felbamate Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
BCC7340 Gavestinel 153436-38-5
BCC6589 (S)-(-)-HA-966 111821-58-0
BCC5946 HU 211 Dexanabinol (HU-211) is an artificially synthesized cannabinoid derivative and lacks cannabimimetic effects. Dexanabinol exhibits not only the antioxidant and neuroprotective activities in brain but also anti-inflammatory activity by inhibiting NF-κB and decreasing cytokines such as TNFα and interleukin-6, which could ensure the integrity of BBB and reduce cell apoptosis and death. Dexanabinol is widely used in head injury or stroke treatment and has been shown to be safe in animals and humans.